DS
ATXS

David Shaw’s Astria Therapeutics ATXS Stock Holding History

David Shaw’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-82,925
Closed -$604K – 4588
2025
Q3 		$604K Buy
82,925
+529
+0.6% +$3.58K ﹤0.01% 3762
2025
Q2 		$442K Buy
82,396
+63,639
+339% +$308K ﹤0.01% 3697
2025
Q1 		$100K Buy
18,757
+7,382
+65% +$51.6K ﹤0.01% 4018
2024
Q4 		$102K Buy
11,375
+1,207
+12% +$12.8K ﹤0.01% 4166
2024
Q3 		$112K Sell
10,168
-14
-0.1% -$156 ﹤0.01% 4241
2024
Q2 		$92.7K Buy
+10,182
New +$99.4K ﹤0.01% 4174
2022
Q2 		– Sell
-24,809
Closed -$166K – 5334
2022
Q1 		$166K Sell
24,809
-13,398
-35% -$79.8K ﹤0.01% 4912
2021
Q4 		$206K Sell
38,207
-7,863
-17% -$51.7K ﹤0.01% 4868
2021
Q3 		$407K Buy
+46,070
New +$441K ﹤0.01% 4201
2016
Q3 		– Sell
-232
Closed -$52K – 3362
2016
Q2 		$52K Hold
232
– – ﹤0.01% 3285
2016
Q1 		$70K Sell
232
-205
-47% -$70.7K ﹤0.01% 3309
2015
Q4 		$208K Sell
437
-91
-17% -$43.7K ﹤0.01% 3542
2015
Q3 		$256K Buy
+528
New +$377K ﹤0.01% 3408

Other funds holding ATXS

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's ATXS Position: Q4 2025 in Review

David Shaw sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 82,925 shares — an estimated $604K sold.

David Shaw first reported a position in ATXS in Q3 2015 and held it in 13 quarters. The position peaked at $604K in Q3 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • David Shaw reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • David Shaw sold 82,925 Astria Therapeutics shares in Q4 2025, an estimated $604K.
  • David Shaw first reported a position in Astria Therapeutics in Q3 2015 and held it in 13 quarters.
  • David Shaw's Astria Therapeutics position peaked at $604K in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.